To boost up the production of COVID-19 vaccine, the Union government has disbursed a financial assistance of Rs 30 crore to Bharat Immunologicals and Biologicals Corporation Limited’s (BIBCOL) Bulandshahr plant to augment the production of Coronavirus vaccine.
The Public Sector Undertaking (PSU) firm will manufacture over 2 crore jabs of India’s indigenous vaccine, Covaxin, every month by the end of August this year. Established over 3 decades back, BIBCOL manufactures oral polio vaccines and other immunisers.
Recently, to speed up the production capacities of Covaxin vaccine, the central government allotted a grant Rs 65 core to Bharat Biotech’s new Bangalore facility which is being repurposed to increase the capacity of vaccine production.
Additionally, two other public sectors companies have been roped in to ramp up the capacity of vaccine production.
Biopharmaceutical Corporation Ltd, a state PSE will be granted approx Rs 65 crore by the government of India to expedite the vaccine production. The facility will have a capacity of 20 million dozes per month, once functional.
Hyderabad-based Indian Immunologicals Limited (IIL), Hyderabad, a facility under National Dairy Development Board has also been roped for the production COVID jabs.
Mission Suraksha for India
To accelerate the development and production of Indigenous COVID vaccines, government of India has rolled out Mission COVID Suraksha last year.
Under the mission, the Union government has been providing financial support as grant to vaccine manufacturing facilities for enhanced production capacities.
The government’s Mission Suraksha aims to increase production of Covaxin by nearly 6-7 crore every month by the end of August 2021. It is expected to reach nearly 10 crore doses per month by September 2021.
The COVID-19 vaccine development mission focus on clinical development and manufacturing and regulatory facilitation, which would consolidate all available and funded resources towards an accelerated product development.
The move aims at developing approx. 5-6 vaccine candidates and brought them closer to licensure for the introduction in public health systems, to combat the spread of COVID-19.